Palma DA, et al. - In patients with a controlled primary tumor and one to five oligometastatic lesions, researchers evaluated the impact of stereotactic ablative radiotherapy (SABR) on survival, oncological outcomes, toxicity, and quality of life. From February 10, 2012 to August 30, 2016, 99 patients were randomized to receive either palliative standard of care treatments alone (control group), or standard of care plus SABR to all metastatic lesions (SABR group). According to this randomized, open-label phase 2 study, overall survival was higher with SABR, which met the primary endpoint of this trial, but three (4.5%) of 66 subjects in the SABR group suffered death related to treatment. An irrefutable survival benefit and the maximum number of metastatic lesions in which SABR provides a benefit need to be demonstrated via a phase 3 study.